newsfilter
← Latest News
PR Newswire·

New clinical data on lecanemab to be presented at CTAD conference 2026

BRCTF
  • Eisai will present new clinical & real-world evidence on lecanemab (Leqembi®) at the CTAD conference in Boston from November 16-19, 2026.
  • Presentations will feature five-year data from the Clarity AD study & findings from the real-world LEADER study across diverse US clinical settings.
  • BioArctic will present a poster detailing the binding profile of lecanemab in the brains of patients with early Alzheimer's disease.
  • The LEADER study analyzes lecanemab usage three years post-FDA approval through a retrospective, multicenter review of real-world data.
  • The Clarity AD oral presentation covers long-term outcomes including core & extension phases, representing one of the longest follow-up datasets for an approved anti-amyloid therapy.
  • Additional key oral presentations will examine real-world safety including ARIA rates across multiple countries & lecanemab treatment with α-synuclein co-pathology in the Clarity AD CSF substudy.
  • Eisai's poster presentations will cover real-world treatment experience including effectiveness, safety, persistence, subcutaneous administration, & biological processes like CSF protein changes.
  • A key symposium on November 18 will focus on the LEADER study regarding utilization, sex-based outcomes, & at-home subcutaneous administration in early Alzheimer's disease.
  • Leqembi is approved in 53 countries & is under regulatory review in 6 regions, with subcutaneous initiation approved in China & Japan in September 2026.
  • BioArctic maintains a long-term collaboration with Eisai for lecanemab development & commercialization, retaining commercial rights in the Nordic region & receiving royalties on global sales.
  • The AHEAD 3-45 Phase 3 study for preclinical Alzheimer's disease has been fully recruited since October 2024 & is a partnership between Eisai, Biogen, & the Alzheimer's Clinical Trial Consortium.
  • BioArctic's proprietary BrainTransporter™ technology is utilized in its broader research portfolio targeting Parkinson's disease, ALS, & additional Alzheimer's projects.